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Abstract
During the last three decades liver cell adenoma and liver cell adenomatosis have emerged as new clinical entities in hepato-
logical practice due to the widespread use of oral contraceptives and increased imaging of the liver. On review of published
series there is evidence that 10% of liver cell adenomas progress to hepatocellular carcinoma, diagnosis is best made by open or
laparoscopic excision biopsy, and the preferred treatment modality is resection of the liver cell adenoma to prevent bleeding
and malignant transformation. In liver cell adenomatosis, the association with oral contraceptive use is not as high as in solitary
liver cell adenomas. The risk of malignant transformation is not increased compared with solitary liver cell adenomas.
Treatment consists of close monitoring and imaging, resection of superficially located, large (44 cm) or growing liver cell
adenomas. Liver transplantation is the last resort in case of substantive concern about malignant transformation or for large,
painful adenomas in liver cell adenomatosis after treatment attempts by liver resection.
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The prevalence of patients with liver cell adenoma is
increasingly seen within hepatology practice due to the
widespread use of oestrogen-based oral contraceptives,
and due to the increased use of cross-sectional imaging
for a variety of unrelated reasons. Consequently many
lesions are identified as incidental findings in asymp-
tomatic patients. The clinical significance and natural
history of these incidental solid liver lesions is not fully
understood, and there is a need for an optimal
management strategy in such patients.
Liver cell adenoma is a benign neoplasm of the liver
that has significant aetiological association with the
oral contraceptive pill in young women. Liver cell
adenoma secondary to oestrogen/progestogen inges-
tion is usually solitary, but some people may develop
several adenomas disseminated throughout the liver.
This latter condition is known as liver cell adeno-
matosis, does not have the strong association with
oestrogen or anabolic steroid ingestion, and affects
males more readily [1].
This article presents the current knowledge and
optimal therapeutic strategies for patients with solitary
liver cell adenoma and liver cell adenomatosis.
Background
Liver cell adenoma is the most important benign
epithelial tumour of the liver, and has an estimated
incidence of 3 per 1 000 000 per year [2]. The annual
incidence is substantially higher with long-term oral
contraceptive use, estimated at 3–4 per 100 000 [3],
but may be less with newer oral contraceptives [4].
Liver cell adenoma was first described by Edmond-
son [5] in 1958 as an encapsulated liver tumour that
does not contain bile ducts, when he identified two
such lesions in 50 000 autopsies. In 1973, Baum [6]
reported the important relationship between oral
contraceptive use and the development of liver cell
adenomas in seven patients. Several subsequent case
series [7,8] in the 1970s supported the hypothesis of an
association between the oral contraceptive pill and liver
cell adenoma, and in 1976 Edmondson [9] published
a case-control study giving further evidence of this
association. The causal relationship between oral
contraceptive medication and liver cell adenoma
appears to be proportional to the hormonal dose and
duration of medication [3,10,11], and is highest in
women over 30 years of age after using oral contra-
ceptives for more than 24 months. It is estimated the
risk of developing an adenoma increases by a factor of 5
after 5 years, and by 25 after 9 years of oral contra-
ceptive usage [11]. Regression of the tumour may
occur after cessation of oral contraceptive usage [12],
and there are reports of progression to hepatocellular
carcinoma many years after stopping oral contra-
ceptives [13–15]. Pregnancy appears to stimulate rapid
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growth in these lesions with risk of potentially fatal
spontaneous rupture, and should be avoided in women
of childbearing age [3].
Other possible aetiologies of liver cell adenoma
include clomiphene [16], methyl testosterone [17],
danazol [18], Klinefelter’s syndrome [19], Types I, III
and IV glycogen storage disease [20,21], and familial
adenomatous polyposis [22].
Liver cell adenoma is usually a solitary nodule that
may reach 30 cm in diameter. Macroscopically these
lesions are smooth and soft on palpation, and range in
colour from white to yellow to brown. On histological
examination adenomas consist of cords of hepatocytes
that have a high glycogen and fat content. The normal
hepatic parenchymal architecture is lacking, with an
absence of portal tracts and hepatic veins.
Liver cell adenomatosis is present in 10%–24%
[23–25] of patients with liver cell adenoma and
presents specific management difficulties. Liver cell
adenomatosis was originally thought to affect males
and females equally, but the most recent series report
a female : male ratio of 7 : 1 and 15 : 1, respectively
[26,27]. There is a strong association between liver cell
adenomatosis and glycogen storage disease, but the
association of liver cell adenomatosis and oral contra-
ceptive or androgenic steroid use [1] is uncertain.
Presentation and diagnosis
Symptomatic patients usually present with right
upper quadrant pain secondary to bleeding within the
liver cell adenoma. At initial presentation these
symptoms are often attributed to cholecystitis, the
most common diagnosis in this patient population.
Liver function tests may be abnormal secondary to
necrosis or haemorrhage, and alkaline phosphatase
is often elevated in those with liver cell adenomatosis.
Some present with an acute abdomen and life threat-
ening haemorrhage secondary to an uncontained
rupture and bleeding into the peritoneal cavity, but
most have a more indolent clinical presentation.
Some liver cell adenomas are picked up incidentally
during imaging studies of the liver or noted during
laparoscopic cholecystectomy. The differential diag-
nosis includes focal nodular hyperplasia, a benign liver
lesion of vascular origin, and well-differentiated
hepatocellular carcinoma. These two lesions can be
difficult to differentiate from adenoma and remain the
diagnostic challenge as they have different therapeutic
implications. Patients with focal nodular hyperplasia
are less likely to be symptomatic or have deranged liver
function tests [28,29].
The ultrasonographic features of liver cell adenomas
are non-specific and may appear iso-, hypo-, or
hyperechoic. The classical appearance is of a well-
demarcated hyper-echoic mass, but central necrosis or
haemorrhage gives rise to heterogeneous echogenicity
that simulates that of focal nodular hyperplasia [30].
The CT appearances of adenoma may be quite vari-
able, but the classical lesion characteristics are best
appreciated with multi-phase helical CT scanning.
Liver cell adenoma shows early phase peripheral
contrast enhancement and subsequent centripetal
contrast enhancement [31]. The pattern of perfusion
starting at the periphery can be demonstrated on
angiography and has been used to differentiate liver cell
adenomas from focal nodular hyperplasia where the
vascular supply arises centrally from a feeding artery
leading to rapid filling of the suprahepatic vein (‘spoke
wheel’ appearance) [32].
Magnetic resonance imaging has the optimal sensi-
tivity for lesion detection, but again characterization of
the lesion can be variable. Ultra-fast sequences with
breath-holding and gadolinium contrast provide most
information [27,33,34], and surveillance of patients
with liver cell adenomatosis is highly effective using a
delayed teslascan 24 hours after injection of gadolinium
(see Figure 1). Even with these advances it may be
impossible to differentiate liver cell adenoma from focal
nodular hyperplasia or hepatocellular carcinoma, and a
biopsy is then essential for histological clarification.
Lesion biopsy
Percutaneous biopsy of a liver lesion is not to be
recommended in young fit patients as this can induce
bleeding and tumour dissemination, does not exclude
malignancy if normal tissue is found, and may be
inaccurate. In a study by Charny et al., only 11 of 30
biopsies were accurate [35]. There are numerous case
reports of women using oral contraceptives who
develop hepatocellular carcinomas, but preoperative or
operative liver needle biopsies reveal liver cell adeno-
mas only [14,36–39] (Table I). Excision biopsy of liver
lesions either by open surgery, or laparoscopically [40],
is the gold standard method for diagnosis. Even with
tumour tissue, accurate microscopic differentiation
between benign liver cell adenomas and hepatocellular
Figure 1. Teslascan MRI at 24 hours after injection: uptake of
contrast in left lobe and lateral aspect of right lobe by multiple
adenomas (arrows).
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carcinoma can be difficult. QBend 10- and erbB2-
immunostaining [41,42], comparative genomic in situ
hybridization [43], and fluorescence in-situ hybrid-
ization [44] may differentiate between hepatic
adenoma and hepatocellular carcinoma but have not
yet entered routine clinical practice.
Complications and management of solitary
liver cell adenoma
Haemorrhage
This is a well-recognized complication of solitary liver
cell adenoma [45–47] and is often the cause of pain in
symptomatic patients. The morphology of adenomas
with their extensive proliferation of blood-filled sinu-
soids, supplied by high-pressure arterial flow, and poor
soft tissue support, makes them prone to bleed. The
frequency of this complication is difficult to estimate,
as this data is omitted in most case series, and many
patients are advised to undergo resection of solitary
liver cell adenoma at diagnosis to prevent a later
presentation with tumour bleeding.
The risk of spontaneous bleeding into, or from, a
ruptured adenoma, is likely to be between 20% and
40%. Selected series have demonstrated evidence of
bleeding on microscopy in 4 of 10 patients [23], 3 of 15
patients on ultrasound, and 4 of 10 patients on contrast
CT [28]. Most bleeding is contained and does not
present a life-threatening event, but bleeding from a
liver cell adenoma can be fatal [48], and in the series
reported by Rooks, 6 of 79 patients (8%) with liver cell
adenoma died due to bleeding [3].
It has been suggested that adenomas greater than
5 cm in diameter should be excised as they are at
increased risk of bleeding [49]. However, Flowers [50]
and Minami [51] reported patients with massive
bleeding from adenomas of only 3.5 cm diameter, with
one patient fatality in the postoperative period. In
contrast, other patients with large adenomas have been
observed for prolonged periods without evidence of
bleeding. Currently there is no evidence to correlate
risk of bleeding with size or number of liver cell
adenomas.
There are numerous reports of bleeding liver cell
adenomas during pregnancy and the puerperium, and
women with known liver cell adenomas should be
strongly advised not to become pregnant [3,52–59].
Excision of a liver cell adenoma has been successfully
performed during the second trimester [52]. Given this
risk and the unpredictable natural history of solitary
liver cell adenoma with respect to bleeding, the
majority of patients should be advised to undergo
surgical resection.
Patients who present with bleeding or rupture will
require surgical resection. However, the extent of
resection and mortality can be reduced by delaying
surgery to allow stabilization of the patient. Inter-
ventional radiological procedures such as hepatic
artery embolization are a useful adjunct in this situation
[60]. Depending on the severity of bleeding the options
are emergency excision on presentation, elective ex-
cision after haemodynamic stabilization or conservative
management with delayed excision [61].
Malignant transformation in solitary liver cell adenoma
There are numerous reports of malignant transfor-
mation of liver cell adenoma to hepatocellular
carcinoma [14,15,37–39,62–65]. Most reported cases
are associated with oral contraceptive use for a pro-
longed period of time. a-fetoprotein levels are often
within normal range in these patients and thus a poor
indicator of tumour progression (Table I).
Most cases of hepatocellular carcinoma develop at
the site of the liver cell adenoma lending support to the
Table I. Malignant transformation of liver adenomas
Length of OC use aFP Liver biopsy Specimen analysis/particularities
Davis M, 1975 [62] 2 years normal – Well-differentiated hepatocellular carcinoma
(HCC) in adenoma
Pryvor AC, 1977 [36] 12 years normal liver adenoma Well-differentiated HCC in adenoma
Tesluk H, 1981 [14] 5 years normal liver adenoma Adenoma regressed after OC stop, but did not
disappear, 3 years later development of HCC.
Gordon SC, 1986 [15] 14 years normal – Adenoma regressed after stop of OC; 5 years later
development of HCC
Gyorffy EJ, 1989 [63] 19 years initially normal,
later on elevated
– Initial percutaneous liver biopsy: liver adenoma
Repeat biopsy 3 years later: HCC
Korula J, 1991 [37] 21 years normal liver adenoma Well-differentiated HCC in adenoma
Ferrell DL, 1993 [38] for 6 months, 5 years
before presentation
unknown liver adenoma Well-differentiated HCC within multilobular
adenoma
Herman P, 1994 [39] 15 years
20 years
unknown
unknown
–
benign
Well-differentiated HCC in adenoma
Well-differentiated HCC in adenoma
Perret AG, 1996 [64] 3 years normal – Disseminated foci of HCC in 14 cm multilobular
adenoma
Ye MQ, 1999 [65] 25 years normal – Well-differentiated HCC in adenoma
OC=oral contraceptives. HCC=hepatocellular carcinoma. aFP=a-fetoprotein.
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hypothesis of a progressive adenoma-carcinoma
sequence. However, some pathologists debate the
malignant potential of liver cell adenomas and consider
them as the end-stage of hepatocyte proliferation
induced by anabolic steroids [66]. The international
working party of hepatocellular lesions takes a cautious
view on the question of malignant potential of liver cell
adenomas and states that ‘malignant progression has
been reported, but is rare’ [67]. Of the 14 series on liver
cell adenoma reported to date [24,28,29,50,60,61,
68–75], 10 series [29,60,61,69–75] have reported
progression or de novo development of hepatocellular
carcinoma within the liver cell adenoma and this occurs
with a frequency of 1 : 12 to 1 : 9 (i.e. 8%–11%)
(Table II). Five of the 10 series [60,67,69,70,73]
specified follow-up ranging between 16–81 months.
One patient died from progressive hepatocellular
carcinoma 18 months following resection [69]. There
have been no reports of recurrence or progression to
liver cell carcinoma in the other patients.
There is a real risk of malignant transformation in the
order of 10%, and this should be seriously considered
when advising patients.
Tao states that oral contraceptive-induced liver cell
adenomas are reversible if oral contraceptives are
discontinued within a certain time period, and that
after prolonged oral contraceptive usage dysplastic foci
develop within the liver cell adenoma that progress to
hepatocellular carcinomas [76].
Fully developed cancers have extensive genomic
damage as the result of their genetic instability
(‘bystander effect’) [77]. Pre-cancerous and benign
tumours have less genetic alterations. Liver cell
adenomas attracted the attention of genetic research
in recent years to identify the initial critical genetic
event in the development of hepatocellular carcinoma.
Results are yet inconclusive and summarized in
Table III.
The etiological role of oral contraceptives in induc-
ing liver cell adenoma is beyond doubt, and many
studies have shown regression and even complete
resolution of adenomas after cessation of the oral
contraceptive pill [90–97]. This observation is not
consistent, as others have not noted any change in the
size of existing liver cell adenomas after discontinu-
ation of oral contraceptives [98,99]. It probably
correlates with the observation that the detection of
hormone receptors in liver cell adenomas varies
between 26% and 73% [100,101]. Discontinuation of
oral contraceptives before surgery is worthwhile, as this
may facilitate adenoma regression and reduce the
extent of liver resection.
It is important to note that even complete resolution
of the adenoma does not prevent the late occurrence of
hepatocellular carcinoma, as this has been observed
3–5 years after cessation of oral contraceptive usage
and regression of the adenoma [14,15]. In contrast,
there are no reports of de novo adenoma occurrence or
formation of hepatocellular carcinoma after primary
resection of solitary liver cell adenoma. This provides a
strong argument in favour of liver resection as the
primary treatment for solitary liver cell adenoma.
Resection of solitary liver cell adenoma
Prevention of bleeding and/or malignant transfor-
mation is guaranteed with surgical resection, but there
is morbidity and mortality associated with surgical
resection. Depending on experience, the morbidity
associated with liver resection for benign tumours
ranges from 10% to 27%, and mortality from 0% to 3%
[49,70].
Despite the risk associated with surgery, we strongly
favour surgical resection of solitary liver cell adenoma
for four reasons. Firstly, the risk of malignant trans-
formation is substantial (around 10%), and regression
of liver cell adenomas after stopping oral contra-
ceptives does not prevent late malignant transfor-
mation. Secondly, bleeding or rupture of a liver cell
adenoma is common and unpredictable, occurring in
Table II. Adenoma series
Patients
Hepatocellular
carcinoma Male Rupture Bleeding
Oral contraceptive
use
Weil R, 1979 [68] 8 0 1
Kerlin P, 1983 [69] 23 2 2 19 : 23
Leese T, 1988 [24] 18 0 16 : 18
Flowers BF, 1990 [50] 6 0 1 2 5 : 5
Belghiti J, 1993 [70] 13 1
Cherqui D, 1995 [28] 6 0 2 CT 3 : 6
MRI 3 : 5
5 : 6
Nagorney DM, 1995 [71] 24 2 2 2 2 9 : 22
Ault GT, 1996 [60] 11 3 1 9 : 10
DeCarlis L, 1997 [72] 19 2 17 : 19
Weimann A, 1997 [29] 44 3 1 6
Ichikawa T, 2000 [73] 25 2 4 CT 11 : 44 12 : 21
Reddy KR, 2001 [74] 25 1 3 22 : 25
Charny CK, 2001 [75] 12 1 2
Marini P, 2002 [61] 7 1 6 7 7 : 7
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30%–50% of such lesions. This bleeding is unrelated to
lesion size or site, and may be fatal. Thirdly, it may be
impossible to differentiate on radiology alone between
an adenoma and a well-differentiated hepatocellular
carcinoma. This necessitates resection and histological
analysis to reassure patient and clinician. Finally,
surgical resection provides a guaranteed long-term
cure and no risk of tumour recurrence. Given these
facts, surgical resection is presently the optimal treat-
ment for all patients that present with solitary liver cell
adenoma.
Liver cell adenomatosis
The same recommendation cannot be made for those
who present with multiple adenomas within the liver.
The clinical entity of liver cell adenomatosis was first
proposed by Flejou et al. in 1985, who described 5
patients with multiple adenomas of the liver and
collated this experience with 8 similar previous case
reports. The characteristic features of liver cell
adenomatosis proposed at that time were (a) arbitrarily
more than 10 tumor nodules in the liver, (b) equal
male/female distribution, (c) no association with oral
contraceptives, (d) increased levels of serum alkaline
phosphatase and g-glutamyl transpeptidase [1].
Multiple adenomas occur in approximately 10%–
24% of all patients with liver cell adenomas [23–25],
and the reason for this remains obscure. Given the
disparate and extensive distribution of lesions in
liver cell adenomatosis, these patients present a more
difficult management problem, as targeted adenoma
excision as for solitary liver cell adenoma is not a
practical option. Chiche et al. have suggested two
distinct patterns of disease with liver cell adenomatosis
[26]. The ‘massive type’ presents with gross hepato-
megaly, a deformed liver contour, and contains many
large tumour nodules ranging from 2–10 cm in
diameter. The massive type may be rapidly progressive
and presents a particular therapeutic challenge.
The ‘multifocal type’ contains many adenomas up to
4 cm in diameter but the liver contour is not deformed
or enlarged. These patients are unlikely to have
symptoms and appear to have a less aggressive clinical
course.
Risk of bleeding
As with solitary liver cell adenoma, patients with liver
cell adenomatosis frequently present with right upper
abdominal pain attributed to bleeding into the
adenoma. As these patients have multiple lesions the
risk of bleeding is substantially higher, occurring in
46% of patients in the series by Flejou et al. [1]. As it is
not possible to resect all adenomatous lesions (except
by liver transplantation), prophylactic liver resection to
prevent bleeding must be targeted to those lesions at
greatest risk of causing life-threatening haemorrhage.
Large lesions 44 cm in diameter, and sub-capsular
lesions that may bleed into the peritoneal cavity, should
be considered for resection to prevent bleeding
[102]. Of the 81 patients with liver cell adenomatosis
described, 15 (18%) have presented with intra-
abdominal bleeding [26,69,103–105], and two
patients died on presentation from intraperitoneal
haemorrhage [26,106].
Risk of malignancy
Chiche et al. challenge the malignant potential of
adenomas in patients with liver cell adenomatosis [26],
primarily as data in this regard are scant. However, six
patients with undisputable liver cell adenomatosis are
known to have undergone malignant transformation
[24,25,27,107,108], with four of the six patients male.
The original observation that liver cell adenomatosis
affected men and women equally is no longer valid, as
the majority of affected individuals (74%) to date are
female [26]. Thus, male sex may be a risk factor for
malignant transformation in liver cell adenomatosis.
The 81 liver cell adenomatosis patients currently
documented in the literature have an average docu-
mented follow-up of 57 months (range 3–180 months),
at which time-point 41 patients have stable disease, 34
patients have progression of disease with increased size
and/or number of lesions, and 6 (7%) have developed
malignancy. At present there is no evidence to suggest
that the risk of malignant transformation is increased in
liver cell adenomatosis compared with that of solitary
adenoma.
Liver transplantation for liver cell adenomatosis
The only potential cure for liver cell adenomatosis is
liver transplantation, and therefore some have
advised organ transplantation for this condition
[69,70,109,110]. The benefit of liver transplantation
to prevent bleeding or cancer in these young patients
has to be balanced against the potential risk of trans-
plantation. Perioperative mortality of liver transplan-
tation is less than 1%, and 5- and 8-year survival are
about 66% and 61% respectively. Most deaths (65%)
occur within the first 6 months [111].
In the longer term, up to 11.5% of liver recipients
have been reported to develop de novo tumours on
immunosuppression [112], renal failure occurs in 10%
after 10 years [113], and hypertension in more than
50% [114]. The rate of leakage or stenosis of the biliary
anastomosis varies between 15% and 33% [115].
Rejection occurs in 3%–5% [116,117].
Of the 17 cases of liver transplantation for liver cell
adenomatosis in the literature [24,27,108,118–120],
outcome and survival are known for 10 patients (see
Table IV). Average length of follow-up is 87 months
(36–145 months). There was one death in the
immediate postoperative period, and three patients
have developed hepatocellular carcinomas in the
transplanted liver or developed lung metastasis
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[27,108]. Two of these three patients did not have any
evidence of malignancy in their native liver. Hepato-
cellular carcinoma in the transplanted organ became
apparent 9 and 12 years after liver transplantation.
This casts considerable doubt on the indication for
transplantation in liver cell adenomatosis to prevent
malignant transformation, as malignant progression
can still occur despite transplantation.
Management of liver cell adenomatosis
Given the morbidity and mortality associated with liver
transplantation, current world experience would
support a more conservative approach as the optimal
initial management strategy. Patients should be
entered into a surveillance program that includes
regular (annual) CT or MRI scanning, and frequent
serum alpha-fetoprotein measurement to detect
progression of disease (increased lesion size) and/or
malignant transformation.
All female patients should be advised to stop
hormone medication (e.g. oral contraceptives,
hormone replacement therapy), and also ensure that
they prevent further pregnancies. Patients presenting
with intraperitoneal bleeding require laparotomy and
resection of the bleeding tumour.
Those who have the massive form of liver cell
adenomatosis may have a preponderance of large
lesions within a single lobe, and are best managed by
hemi-hepatectomy. Patients with multifocal liver cell
adenomatosis should be monitored with regular liver
imaging. Progression of disease with large subcapsular
adenomas (44 cm), concern of malignant transfor-
mation, and increasing symptoms are indications for
resection in multifocal liver cell adenomatosis. Re-
section is the preferable option unless technically im-
possible. Orthotopic liver transplantation should be
considered only as a last resort. Indications where
transplantation is considered may include rise in serum
alpha-fetoprotein, concern about malignant transfor-
mation on imaging, and symptomatic patients with
marked hepatomegaly and a history of repeated
adenoma complications [24,26].
Conclusion
Liver cell adenoma is the most important benign
tumour of the liver because of its frequency and
potential for complications which are life threatening:
bleeding and malignant transformation. Despite
significant progress in imaging, definite diagnosis is by
excision biopsy.
Discontinuation of oral contraceptives is often
associated with regression of the adenoma, but there is
still a risk of malignant transformation. Because of the
risks of bleeding and malignant transformation surgical
excision is the preferred treatment option for solitary
liver cell adenomas.
Liver cell adenomatosis provides a clinical challenge.
Symptomatic tumours, which are accessible to surgery,
should be resected. The role of transplantation
remains unclear. Other treatment modalities such as
embolization of bleeding tumours and radiofrequency
ablation may be useful adjuncts in selected cases.
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